-
Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates
-
Sun Pharma to Acquire Checkpoint Therapeutics
-
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)
-
Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024e
